Evidence map›Paper›PMID 35585292›Full record

ReviewReproductive sciences (Thousand Oaks, Calif.)2023

Current Update on Nanotechnology-Based Approaches in Ovarian Cancer Therapy.

Boddapati Kalyani Bhardwaj, Sanu Thankachan, Priyanila Magesh, Thejaswini Venkatesh, Rie Tsutsumi, Padmanaban S Suresh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Reproductive sciences (Thousand Oaks, Calif.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. New trends in diagnosing and treating ovarian cancer using nanotechnology.Frontiers in bioengineering and biotechnology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Boddapati Kalyani BhardwajSchool of Biotechnology, National Institute of Technology, Calicut-673601, Kerala, India.
Sanu ThankachanSchool of Biotechnology, National Institute of Technology, Calicut-673601, Kerala, India.
Priyanila MageshSchool of Biotechnology, National Institute of Technology, Calicut-673601, Kerala, India.
Thejaswini VenkateshDept of Biochemistry and Molecular Biology, Central University of Kerala, Kasargod, 671316, Kerala, India.
Rie TsutsumiDepartment of Nutrition and Metabolism, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15, Kuramoto-cho, Tokushima City, 770-8503, Japan.
Padmanaban S SureshSchool of Biotechnology, National Institute of Technology, Calicut-673601, Kerala, India. surepadman@gmail.com.ORCID 0000-0002-6126-2974
National Institute of Technology Calicut · INCentral University of Kerala · INTokushima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is one of the leading causes of cancer-related deaths among women. The drawbacks of conventional therapeutic strategies encourage researchers to look for alternative strategies, including nanotechnology. Nanotechnology is one of the upcoming domains of science that is rechanneled towards targeted cancer therapy and diagnosis. Nanocarriers such as dendrimers, liposomes, polymer micelles, and polymer nanoparticles present distinct surface characteristics in morphology, surface chemistry, and mode of action that help differentiate normal and malignant cells, which paves the way for target-specific drug delivery. Similarly, nanoparticles have been strategically utilized as efficacious vehicles to deliver drugs that alter the epigenetic modifications in epigenetic therapy. Some studies suggest that the use of specialized target-modified nanoparticles in siRNA-based nanotherapy prevents internalization and improves the antitumor activity of siRNA by ensuring unrestrained entry of siRNA into the tumor vasculature and efficient intracellular delivery of siRNA. Moreover, research findings highlight the significance of utilizing nanoparticles as depots for photosensitive drugs in photodynamic therapy. The applicability of nanoparticles is further extended to medical imaging. They serve as contrast agents in combination with conventional imaging modalities such as MRI, CT, and fluorescence-based imaging to produce vivid and enhanced images of tumors. Therefore, this review aims to explore and delve deeper into the advent of various nanotechnology-based therapeutic and imaging techniques that provide non-invasive and effective means to tackle ovarian cancers.

Indexed as

NeoplasmsOvarian NeoplasmsDrug Delivery SystemsFemaleHumansNanotechnologyPolymersRNA, Small InterferingPolymersRNA, Small InterferingDendrimersLiposomesOvarian cancerPolymer nanoparticles

Identifiers

PMID35585292
OpenAlexW4280510069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.